These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 38215)

  • 41. [Pharmacology of new beta-adrenergic receptor blocking drugs. II. Bronchopulmonary and cardiovascular effects of VUL 111 and trimepranol (author's transl)].
    Drímal J; Seginko J; Gibala P; Strízová K
    Bratisl Lek Listy; 1978 Oct; 70(4):429-39. PubMed ID: 31233
    [No Abstract]   [Full Text] [Related]  

  • 42. [The effect of adrenergic beta receptor blockers on phospholipid metabolism in mast cells].
    Pecivová J; Drábiková K; Nosál' R
    Bratisl Lek Listy; 1990 May; 91(5):363-8. PubMed ID: 1974476
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Local anesthetic action of metipranolol as compared to timolol].
    Draeger J; Schneider B; Winter R
    Klin Monbl Augenheilkd; 1983 Mar; 182(3):210-3. PubMed ID: 6133977
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.
    Lapka R; Sechser T; Rejholec V; Peterková M; Votavová M
    Eur J Clin Pharmacol; 1990; 38(3):243-7. PubMed ID: 1971217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute effect of metipranolol on the retinal circulation.
    Wolf S; Werner E; Schulte K; Reim M
    Br J Ophthalmol; 1998 Aug; 82(8):892-6. PubMed ID: 9828772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmacological demonstration of beta 1 selectivity of beta-receptor blockaders].
    Lundgren B; Carlsson E; Ablad B
    Med Welt; 1978 Sep; 29(39):1531. PubMed ID: 29208
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical pharmacology of trimepranol (pharmacokinetic informations and effects on heart rate in healthy individuals)].
    Mayer O; Petrlík M; Vitous J; Cepelák V
    Vnitr Lek; 1976 Nov; 22(11):1102-9. PubMed ID: 12612
    [No Abstract]   [Full Text] [Related]  

  • 48. A study on the ocular and extraocular pharmacology of metipranolol.
    Sugrue MF; Armstrong JM; Gautheron P; Mallorga P; Viader MP
    Graefes Arch Clin Exp Ophthalmol; 1985; 222(3):123-7. PubMed ID: 2858433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Experience in treatment of patients with ischemic heart disease by means of beta adrenergic blocking agents].
    Lebedev SV
    Klin Med (Mosk); 1977 May; 55(5):54-7. PubMed ID: 17769
    [No Abstract]   [Full Text] [Related]  

  • 50. BM 12.434, a novel compound with vasodilating and beta-adrenoceptor-blocking activities.
    von Möllendorff E; Huschka C; Schröter E; Abshagen U
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():477s-479s. PubMed ID: 6119183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The effect of stress factors on the ultrastructure of the myocardium and creatinine kinase activity in the blood of rats premedicated with metipranolol].
    Tureková L; Belanová M; Bózner A; Inczinger F
    Cesk Patol; 1981 Nov; 17(4):209-15. PubMed ID: 6120044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Integrated electrophysiological examination for the purpose of elucidating the effects of beta blockaders].
    Rauser V
    Fysiatr Revmatol Vestn; 1979 Jun; 57(3):181-3. PubMed ID: 37149
    [No Abstract]   [Full Text] [Related]  

  • 53. [Contribution to the analysis of the mechanism of rebound phenomenon development following beta blockers (author's transl)].
    Svec P; Béderová E; Tumová I; Inczinger F
    Bratisl Lek Listy; 1979 Apr; 71(4):470-80. PubMed ID: 36211
    [No Abstract]   [Full Text] [Related]  

  • 54. Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects.
    Janků I; Perlík F; Tkaczyková M; Brodanová M
    Eur J Clin Pharmacol; 1992; 42(3):337-40. PubMed ID: 1349528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Conjunctival keratinisation, an abnormal reaction to an ocular beta-blocker.
    Derous D; de Keizer RJ; de Wolff-Rouendaal D; Soudijn W
    Acta Ophthalmol (Copenh); 1989 Jun; 67(3):333-8. PubMed ID: 2475010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contact allergy to metipranolol.
    de Groot AC; Conemans J
    Contact Dermatitis; 1988 Feb; 18(2):107-8. PubMed ID: 2896579
    [No Abstract]   [Full Text] [Related]  

  • 57. Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension.
    Battershill PE; Sorkin EM
    Drugs; 1988 Nov; 36(5):601-15. PubMed ID: 2905641
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of beta-blocking agent Metipranolol on metabolic variables in patients with ischemic heart disease, hyperkinetic syndrome, hyperthyreosis and in healthy subjects.
    Ceremuzynski L; Zaleska T; Nauman J; Nauman A; Zalewski A
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):244-9. PubMed ID: 38215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beta-blocking drug metipranolol: plasma levels and pharmacodynamic action in man.
    Mayer O; Cepelák V; Vitous J; Potmĕsil J
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):113-9. PubMed ID: 6103879
    [No Abstract]   [Full Text] [Related]  

  • 60. [The effect of the beta-blockers nadolol and metipranolol in patients with thyrotoxicosis].
    Vavrejnová V; Felt V; Nedvídková J
    Cas Lek Cesk; 1985 Oct; 124(43):1320-3. PubMed ID: 2867827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.